Company Overview and News

 
NZ shares gain as investors take stock in earnings season

2018-08-17 nzherald.co.nz
New Zealand shares rose as investors took stock in a brief lull to the domestic corporate earnings season, with Skellerup Holdings extending yesterday's gain to break a new record.
CEN AIR NZTCF RYM ACKDF ANZFY AUKNY AIZ COENF GNE AOTUF SKC PPSHY CEN SNZ SKL GEL AIA RHCGF SPKKY NZTCY SPK COENY AIA THL ANZLY RYHTY SKLUY ANZFF GNE MEZ

 
Precinct Properties New Zealand Ltd 2018 Q4 - Results - Earnings Call Slides

2018-08-16 seekingalpha
The following slide deck was published by Precinct Properties New Zealand Ltd in conjunction with their 2018 Q4 earnings call.
AOTUF

 
NZ shares rise as Skellerup posts record profit

2018-08-16 nzherald.co.nz
New Zealand shares rose, led higher by a record profit from Skellerup Holdings, as investors focused more on domestic earnings than volatility in global markets. Precinct Properties New Zealand also gained.
CEN AIA FBU FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF AUKNY COENY COENF AOTUF SKC AIA FBU CEN SKLUY SKL PFGTF SML

 
NZ shares rise as earnings continue

2018-08-15 nzherald.co.nz
New Zealand shares rose as earnings season continued to deliver mixed results. NZX was among gainers on the day after delivering a special dividend while Heartland Bank fell on its increased bad debt provisioning.
AIA SPKKY NZTCY SPK NZTCF WDT ACKDF AUKNY SKT AOTUF SYKWF AIA SKKTY SKLUY SKL MEZ WFVLF SML

 
Precinct Properties earns Morningstar upgrade on ANZ Centre deal

2018-07-06 nzherald.co.nz
Shares of Precinct Properties New Zealand earned an upgrade from Morningstar following the commercial property investor's deal, announced last week, to sell 50 per cent of the ANZ Centre in Auckland's central business district for $181 million.
AOTUF

26
NZ shares taper off in strong June quarter

2018-06-29 nzherald.co.nz
New Zealand shares ran out of puff in the final day of the June quarter, which has been the strongest quarterly performance in more than two years. Summerset Group Holdings and Ebos Group declined and Westpac Banking Corp gained.
SGM FCREY NZTCF SMSMY ACKDF AUKNY FTRRF KMD SMUPF AOTUF SNZ KMD SML KTHDY AIA FBU WBC SCY SPKKY NZTCY EBOSY SPK WEBNF WBK FRCEF EBO EBOSF AIA WBC FBU EBO

17
NZ shares rebound, led by Precinct Properties

2018-06-20 nzherald.co.nz
New Zealand shares rebounded from yesterday's 1.2 percent loss, led higher by Precinct Properties New Zealand and Westpac Banking Corp.
WBC SPKKY NZTCY SPK NZTCF WEBNF WBK SKT GNE AOTUF SYKWF WBC PPSHY SNZ SKKTY GNE GEL SML

14
A2 Milk drops 3 per cent as sharemarket edges lower

2018-05-22 nzherald.co.nz
New Zealand shares fell, led lower by continued selling in A2 Milk Co and Comvita, while Ryman Healthcare and Heartland Bank gained.
KTHDY CEN NMR RHCGF RYM COENY KMD COENF AOTUF 8604 SKC AFP N33 RYHTY NRSCF CEN KMD

30
NZ shares up as A2 leads index

2018-05-02 nzherald.co.nz
New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.
CEN FCREY NZTCF RYM KMD COENF GNE AOTUF CEN KMD GEL KTHDY FBU WBC RHCGF SPKKY NZTCY SPK WEBNF WBK FRCEF COENY WBC FBU RYHTY GNE GTK MEZ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...